Chengdu Shengnuo Biopharm Co.,Ltd.
As of 18 November 2026, for the company name Chengdu Shengnuo Biopharm Co.,Ltd. as recorded, the chemical-drug catalogue lists 13 active records with this name as holder; 27 active API registrations list this name as first registered company.
Check drug filings and source records for this company-name string.
Listed by the company name as recorded in the source, without merging affiliated entities.
Page reference
These counts cover loaded acceptance records only. First-applicant and co-applicant counts are not added together. CDE data as of 2026/11/18.
Drug filings
18 acceptance records as first applicant, grouped into 12 source drug names. Source data as of 2026/11/18.
This source was last successfully updated at 2026/11/18; current coverage may be incomplete.
Acceptance records are de-duplicated by acceptance number. Drug names are normalized only for width and whitespace; dosage forms and combinations remain separate. Application types are retained from the source. Expand a drug to inspect each record. Published drugs link to their drug pages; other names do not create new public drug pages.
Octreotide Acetate Injection 2 records · Latest accepted 2026/04/16
Supplement · 2
特立帕肽注射液 · No verified English name 1 records · Latest accepted 2025/07/30
New drug · 1
| Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|
| CXHL2500773 | New drug | 2025/07/30 | Chengdu Shengnuo Biopharm Co.,Ltd. | CDE ↗ |
Exenatide Injection 3 records · Latest accepted 2025/02/18
Generic · 3
Terlipressin Acetate Injection 1 records · Latest accepted 2024/11/23
Generic · 1
| Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|
| CYHS2404027 | Generic | 2024/11/23 | Chengdu Shengnuo Biopharm Co.,Ltd. | CDE ↗ |
Linaclotide Capsules 1 records · Latest accepted 2024/11/08
Generic · 1
| Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|
| CYHS2403816 | Generic | 2024/11/08 | Chengdu Shengnuo Biopharm Co.,Ltd. | CDE ↗ |
泊沙康唑注射液 · No verified English name 2 records · Latest accepted 2024/07/25
Supplement · 1Generic · 1
Ganirelix Injection 1 records · Latest accepted 2024/01/23
Generic · 1
| Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|
| CYHS2400298 | Generic | 2024/01/23 | Chengdu Shengnuo Biopharm Co.,Ltd. | CDE ↗ |
Carbetocin Injection 2 records · Latest accepted 2023/11/22
Supplement · 2
Levosimendan Injection 1 records · Latest accepted 2023/02/01
Supplement · 1
| Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|
| CYHB2350115 | Supplement | 2023/02/01 | Chengdu Shengnuo Biopharm Co.,Ltd. | CDE ↗ |
Thymalfasin for Injection 1 records · Latest accepted 2021/11/17
Supplement · 1
| Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|
| CYHB2150996 | Supplement | 2021/11/17 | Chengdu Shengnuo Biopharm Co.,Ltd. | CDE ↗ |
Atosiban Acetate Injection 2 records · Latest accepted 2021/07/12
Supplement · 2
Somatostatin For Injection 1 records · Latest accepted 2021/05/12
Supplement · 1
| Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|
| CYHB2150574 | Supplement | 2021/05/12 | Chengdu Shengnuo Biopharm Co.,Ltd. | CDE ↗ |
Changes in the last 90 days
2 events from 2026/08/22 to 2026/11/19. CDE data as of 2026/11/18; NMPA data as of 2026/11/19.
This source was last successfully updated at 2026/11/18; current coverage may be incomplete.
Last 90 days, ordered by fact date. Marketing approvals, trial registrations, supplements, notices and review changes are labelled separately. Fact dates are approval dates, acceptance dates, trial first-publication dates, or the date an application stopped being listed as under review. Publication dates and dates added to this site are listed separately. Historical records with earlier dates are not current-period new events. Exit records cover currently inactive applications whose delisting date is known, not a full review history.
No longer listed under review: 1 applicationSupplement delivery: 1 application
- 2026/11/12No longer listed under review
Octreotide Acetate Injection
CYHB2600762
Fact date: 2026/11/12 · Date added to this site: 2026/11/12
Accepted: 2026/04/16
no longer on the CDE under-review list as of the data cut-off; NMPA published approval-document delivery for this acceptance number on 2026/11/13 (approval no.: 国药准字H20269267; approval date: 2026/11/10); this is a supplemental application, not counted as a new marketing approval · NMPA source · row 31
NMPA · Table row 31 ↗ View source ↗ - 2026/11/10Supplement delivery
Octreotide Acetate Injection
CYHB2600762 · 国药准字H20269267
Fact date: 2026/11/10 · Publication date: 2026/11/13 · Date added to this site: 2026/11/14
Supplemental application; excluded from new marketing approvals.
View source · Table row 31 ↗
Under review
0 acceptance numbers with this company as first applicant are currently listed as under review by CDE. Source data as of 2026/11/18.
This source was last successfully updated at 2026/11/18; current coverage may be incomplete.
| Drug | Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|---|
| No matching records were found in the currently loaded source data; coverage dates are listed below. | |||||
Catalogue holder records
13 loaded active catalogue records whose holder name matches this source company name. Source data as of 2026/11/18. Manufacturer-only records are excluded.
| Drug | Marketing authorization holder | Manufacturer | Approval number | Approved | Catalogue category (source text) | View source |
|---|---|---|---|---|---|---|
| Linaclotide Capsules | Chengdu Shengnuo Biopharm Co.,Ltd. | Chengdu Shengnuo Biopharm Co.,Ltd. | 国药准字H20265774 | 2026/09/02 | Generic approved under the new chemical-drug registration classification | CDE ↗ |
| Exenatide Injection | Chengdu Shengnuo Biopharm Co.,Ltd. | Chengdu Shengnuo Biopharm Co.,Ltd. | 国药准字H20256237 | 2025/12/09 | Generic approved under the new chemical-drug registration classification | CDE ↗ |
| Ganirelix Injection | Chengdu Shengnuo Biopharm Co.,Ltd. | Chengdu Shengnuo Biopharm Co.,Ltd. | 国药准字H20254873 | 2025/07/15 | Generic approved under the new chemical-drug registration classification | CDE ↗ |
| Exenatide Injection | Chengdu Shengnuo Biopharm Co.,Ltd. | Chengdu Shengnuo Biopharm Co.,Ltd. | 国药准字H20254605 | 2025/06/24 | Generic approved under the new chemical-drug registration classification | CDE ↗ |
| 泊沙康唑注射液 · No verified English name | Chengdu Shengnuo Biopharm Co.,Ltd. | Chengdu Shengnuo Biopharm Co.,Ltd. | 国药准字H20243579 | 2024/04/24 | Generic approved under the new chemical-drug registration classification | CDE ↗ |
| Levosimendan Injection | Chengdu Shengnuo Biopharm Co.,Ltd. | Chengdu Shengnuo Biopharm Co.,Ltd. | 国药准字H20110104 | 2024/02/18 | Drug that passed quality-and-efficacy consistency evaluation | CDE ↗ |
| Carbetocin Injection | Chengdu Shengnuo Biopharm Co.,Ltd. | Chengdu Shengnuo Biopharm Co.,Ltd. | 国药准字H20163001 | 2023/08/31 | Drug that passed quality-and-efficacy consistency evaluation | CDE ↗ |
| Thymalfasin for Injection | Chengdu Shengnuo Biopharm Co.,Ltd. | Chengdu Shengnuo Biopharm Co.,Ltd. | 国药准字H20143112 | 2023/01/11 | Drug that passed quality-and-efficacy consistency evaluation | CDE ↗ |
| Atosiban Acetate Injection | Chengdu Shengnuo Biopharm Co.,Ltd. | Chengdu Shengnuo Biopharm Co.,Ltd. | 国药准字H20184094 | 2022/08/31 | Drug that passed quality-and-efficacy consistency evaluation | CDE ↗ |
| Atosiban Acetate Injection | Chengdu Shengnuo Biopharm Co.,Ltd. | Chengdu Shengnuo Biopharm Co.,Ltd. | 国药准字H20173256 | 2022/08/31 | Drug that passed quality-and-efficacy consistency evaluation | CDE ↗ |
| Octreotide Acetate Injection | Chengdu Shengnuo Biopharm Co.,Ltd. | Chengdu Shengnuo Biopharm Co.,Ltd. | 国药准字H20153159 | 2022/07/07 | Drug that passed quality-and-efficacy consistency evaluation | CDE ↗ |
| Somatostatin For Injection | Chengdu Shengnuo Biopharm Co.,Ltd. | Chengdu Shengnuo Biopharm Co.,Ltd. | 国药准字H20183249 | 2022/07/05 | Drug that passed quality-and-efficacy consistency evaluation | CDE ↗ |
| Eptifibatide Injection | Chengdu Shengnuo Biopharm Co.,Ltd. | Chengdu Shengnuo Biopharm Co.,Ltd. | 国药准字H20203646 | 2020/12/08 | Generic approved under the new chemical-drug registration classification | CDE ↗ |
Only active catalogue records matching the source holder name are listed. A manufacturer role does not count as a holder record. The catalogue covers only part of the chemical-drug market; source categories do not establish complete market coverage or qualifications.
API registrations
27 loaded active API registrations whose first registered company matches this source company name. Source data as of 2026/11/18.
| Name | Company / applicant | Registration number | Status | Source update date | View source |
|---|---|---|---|---|---|
| 鲑降钙素 · No verified English name | Chengdu Shengnuo Biopharm Co.,Ltd. | Y20250001368 | I | 2025/12/25 | CDE ↗ |
| 醋酸去氨加压素 · No verified English name | Chengdu Shengnuo Biopharm Co.,Ltd. | Y20250000948 | I | 2025/09/17 | CDE ↗ |
| 培来加南 · No verified English name | Chengdu Shengnuo Biopharm Co.,Ltd. | Y20240001346 | A | 2026/06/25 | CDE ↗ |
| 缩宫素 · No verified English name | Chengdu Shengnuo Biopharm Co.,Ltd. | Y20240001217 | A | 2026/06/04 | CDE ↗ |
| 醋酸特利加压素 · No verified English name | Chengdu Shengnuo Biopharm Co.,Ltd. | Y20240000973 | A | 2026/08/28 | CDE ↗ |
| 利那洛肽 · No verified English name | Chengdu Shengnuo Biopharm Co.,Ltd. | Y20240000089 | A | 2026/03/02 | CDE ↗ |
| 维培那肽 · No verified English name | Chengdu Shengnuo Biopharm Co.,Ltd. | Y20230000631 | A | 2025/12/18 | CDE ↗ |
| 醋酸艾替班特 · No verified English name | Chengdu Shengnuo Biopharm Co.,Ltd. | Y20220001345 | A | 2024/10/11 | CDE ↗ |
| 醋酸西曲瑞克 · No verified English name | Chengdu Shengnuo Biopharm Co.,Ltd. | Y20220000342 | A | 2024/02/23 | CDE ↗ |
| 泊沙康唑 · No verified English name | Chengdu Shengnuo Biopharm Co.,Ltd. | Y20220000311 | A | 2024/03/19 | CDE ↗ |
| 醋酸加尼瑞克 · No verified English name | Chengdu Shengnuo Biopharm Co.,Ltd. | Y20210000010 | A | 2022/11/04 | CDE ↗ |
| 利那洛肽 · No verified English name | Chengdu Shengnuo Biopharm Co.,Ltd. | Y20200001056 | I | 2020/11/06 | CDE ↗ |
| 枸橼酸倍维巴肽 · No verified English name | Chengdu Shengnuo Biopharm Co.,Ltd. | Y20190021501 | A | 2024/07/03 | CDE ↗ |
| 特立帕肽 · No verified English name | Chengdu Shengnuo Biopharm Co.,Ltd. | Y20200000763 | I | 2020/07/23 | CDE ↗ |
| 醋酸奥曲肽 · No verified English name | Chengdu Shengnuo Biopharm Co.,Ltd. | Y20190007931 | A | 2025/07/04 | CDE ↗ |
| 恩夫韦肽 · No verified English name | Chengdu Shengnuo Biopharm Co.,Ltd. | Y20190007396 | A | — | CDE ↗ |
| 生长抑素 · No verified English name | Chengdu Shengnuo Biopharm Co.,Ltd. | Y20190007382 | A | 2024/01/17 | CDE ↗ |
| 胸腺法新 · No verified English name | Chengdu Shengnuo Biopharm Co.,Ltd. | Y20190007213 | A | 2024/11/29 | CDE ↗ |
| 醋酸阿托西班 · No verified English name | Chengdu Shengnuo Biopharm Co.,Ltd. | Y20190006802 | A | 2026/08/08 | CDE ↗ |
| 胸腺五肽 · No verified English name | Chengdu Shengnuo Biopharm Co.,Ltd. | Y20190006694 | A | 2023/03/24 | CDE ↗ |
| 左西孟旦 · No verified English name | Chengdu Shengnuo Biopharm Co.,Ltd. | Y20190006426 | A | 2026/05/11 | CDE ↗ |
| 卡贝缩宫素 · No verified English name | Chengdu Shengnuo Biopharm Co.,Ltd. | Y20190005921 | A | 2025/09/16 | CDE ↗ |
| 利拉鲁肽 · No verified English name | Chengdu Shengnuo Biopharm Co.,Ltd. | Y20180001759 | I | — | CDE ↗ |
| 比伐芦定 · No verified English name | Chengdu Shengnuo Biopharm Co.,Ltd. | Y20170002315 | A | 2026/04/16 | CDE ↗ |
| 依替巴肽 · No verified English name | Chengdu Shengnuo Biopharm Co.,Ltd. | Y20170001653 | A | 2025/09/16 | CDE ↗ |
| 醋酸特利加压素 · No verified English name | Chengdu Shengnuo Biopharm Co.,Ltd. | Y20170001257 | I | — | CDE ↗ |
| 艾塞那肽等29个品种(详见品种信息表) · No verified English name | Chengdu Shengnuo Biopharm Co.,Ltd. | Y20170000554 | A | 2025/11/01 | CDE ↗ |
Only loaded active API registrations not listed as cancelled are shown. A/I are source registration statuses. Records are listed by registration number and do not establish capacity or supply. The register does not identify the associated formulation.
Co-applicant records
0 acceptance records name this company after the first applicant. They are listed separately and are not included in first-applicant drug or filing counts. Source data as of 2026/11/18.
This source was last successfully updated at 2026/11/18; current coverage may be incomplete.
| Drug | Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|---|
| No matching records were found in the currently loaded source data; coverage dates are listed below. | |||||
How current is each source?
- CDE acceptances and review
- Last successful update: 2026/11/18 · Current coverage may be incomplete
- Chemical-drug catalogue
- Last successful update: 2026/11/18
- API registrations
- Last successful update: 2026/11/18
- NMPA drug delivery notices
- Last successful update: 2026/11/19
Loaded notices dated 2026-11-05 to 2026-11-19; 0 notices not yet loaded. Covers loaded notices only, not a complete historical approval database.
Listed by the company name as recorded in the source, without merging affiliated entities.
This page summarizes loaded records only. Parent companies, subsidiaries, former names and aliases are not merged. Counts from different sources must not be added together. No loaded record does not establish the absence of a filing or registration. Check original records where coverage is incomplete, an update has failed, or a source lies outside the loaded scope.
Fact dates are approval dates, acceptance dates, trial first-publication dates, or the date an application stopped being listed as under review. Publication dates and dates added to this site are listed separately. Historical records with earlier dates are not current-period new events. Exit records cover currently inactive applications whose delisting date is known, not a full review history.
Drugs with a verified official English name use that name only. Other drug names retain the Chinese source name marked No verified English name; names with a Chinese public page link to that page. Company labels use verified official names, Latin source names, then fixed-rule transliterations marked romanized; Chinese company names are not displayed. Marked unverified drug names and original statutory reference numbers may appear in Chinese.
Legal reference identifiers are retained verbatim. Company labels use official English entries where available, or a visibly marked fixed romanization. Unverified drug names retain the Chinese source name with a No verified English name marker. Other Chinese free text is not displayed; use the source links or source-name columns in CSV exports.